Literature DB >> 1732773

Müllerian inhibiting substance as a marker for ovarian sex-cord tumor.

M L Gustafson1, M M Lee, R E Scully, A C Moncure, T Hirakawa, A Goodman, H G Muntz, P K Donahoe, D T MacLaughlin, A F Fuller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1732773     DOI： 10.1056/NEJM199202133260707

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

1.  Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model.

Authors:  V Gupta; J L Carey; H Kawakubo; A Muzikansky; J E Green; P K Donahoe; D T MacLaughlin; S Maheswaran
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

2.  Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.

Authors:  A E Stephen; P T Masiakos; D L Segev; J P Vacanti; P K Donahoe; D T MacLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

3.  AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy.

Authors:  Motohiro Kano; Amanda E Sosulski; LiHua Zhang; Hatice D Saatcioglu; Dan Wang; Nicholas Nagykery; Mary E Sabatini; Guangping Gao; Patricia K Donahoe; David Pépin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

Review 4.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

5.  Serum Müllerian Inhibiting Substance/anti-Müllerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology.

Authors:  Henry L Chang; Nima Pahlavan; Elkan F Halpern; David T MacLaughlin
Journal:  Gynecol Oncol       Date:  2009-04-08       Impact factor: 5.482

6.  Testicular dysgenesis does not affect expression of anti-müllerian hormone by Sertoli cells in premeiotic seminiferous tubules.

Authors:  R Rey; L al-Attar; F Louis; F Jaubert; P Barbet; C Nihoul-Fékété; J L Chaussain; N Josso
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

7.  Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance.

Authors:  Thanos D Papakostas; Rafael Pieretti-Vanmarcke; Fotini Nicolaou; Aristomenis Thanos; George Trichonas; Xanthi Koufomichali; Kosisochukwu Anago; Patricia K Donahoe; Jose Teixeira; David T MacLaughlin; Demetrios Vavvas
Journal:  Protein Expr Purif       Date:  2009-09-13       Impact factor: 1.650

8.  Granulosa cell tumor associated with secondary amenorrhea and serum luteinizing hormone elevation.

Authors:  Kaei Nasu; Junichiro Fukuda; Jun Yoshimatsu; Noriyuki Takai; Kenji Kashima; Hisashi Narahara
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

9.  Smad1-Smad5 ovarian conditional knockout mice develop a disease profile similar to the juvenile form of human granulosa cell tumors.

Authors:  Brooke S Middlebrook; Karen Eldin; Xiaohui Li; Sujatha Shivasankaran; Stephanie A Pangas
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

10.  Hormonally Functional Ovarian Neoplasms.

Authors:  Lawrence M. Roth; Steven D. Billings
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.